<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Heart failure in children: Etiology, clinical manifestations, and diagnosis</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Heart failure in children: Etiology, clinical manifestations, and diagnosis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Heart failure in children: Etiology, clinical manifestations, and diagnosis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rakesh K Singh, MD, MS</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">TP Singh, MD, MSc</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John K Triedman, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Carrie Armsby, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 23, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H23884829"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Heart failure (HF) results from structural or functional cardiac disorders that impair the ability of the ventricle(s) to fill with and/or eject blood. The presentation of pediatric HF is diverse because of the numerous underlying cardiac etiologies  (<a class="graphic graphic_table graphicRef79989" href="/d/graphic/79989.html" rel="external">table 1</a>) and varying clinical settings.</p><p>The etiology, clinical manifestations, and diagnostic evaluation of HF in children are reviewed here. The management of HF in children is discussed separately. (See  <a class="medical medical_review" href="/d/html/14520.html" rel="external">"Heart failure in children: Management"</a>.)</p><p class="headingAnchor" id="H804351820"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>In the United States, HF is estimated to affect 12,000 to 35,000 children below the age of 19 years in the United States each year [<a href="#rid1">1,2</a>]. HF-related hospitalizations account for approximately 11,000 to 14,000 hospitalizations in children per year in the United States [<a href="#rid2">2</a>]. Pediatric HF-related hospitalizations are associated with a higher length of stay, readmission rate, hospital charges, and mortality rate compared with non HF-related admissions [<a href="#rid2">2-5</a>].</p><p class="headingAnchor" id="H23884815"><span class="h1">ETIOLOGY AND PATHOPHYSIOLOGY</span><span class="headingEndMark"> — </span>The causes of pediatric HF can be divided into pathophysiologic categories  (<a class="graphic graphic_table graphicRef79989" href="/d/graphic/79989.html" rel="external">table 1</a>). This categorization helps in the understanding of the underlying physiology and clinical manifestations of the different causes of pediatric HF and guides the approach to management. It is important to recognize, however, that these categories may overlap in some patients (eg, volume overload and pressure overload can be associated with ventricular dysfunction).</p><p class="headingAnchor" id="H180717383"><span class="h2">Ventricular dysfunction</span><span class="headingEndMark"> — </span>The cardiac causes of ventricular dysfunction can be separated into children with structurally normal hearts and those born with congenital heart disease (CHD)  (<a class="graphic graphic_table graphicRef79989" href="/d/graphic/79989.html" rel="external">table 1</a>).</p><p class="headingAnchor" id="H180717491"><span class="h3">Structurally normal heart</span><span class="headingEndMark"> — </span>Ventricular dysfunction leads to impaired ejection of blood from the ventricle. Unless specified, ventricular dysfunction implies systolic dysfunction (reduced ventricular contractility). Ventricular diastolic dysfunction implies impaired ventricular filling and noncompliance with abnormally steep pressure-volume relationship, resulting in high ventricular filling pressures. Ventricular dysfunction (systolic or diastolic) can occur in children with CHD and in those with structurally normal hearts. Children with CHD may have ventricular dysfunction at presentation but more commonly develop dysfunction and HF several years (or even decades) following surgical repair of their cardiac defect (ie, "burnt-out" CHD).</p><p>Causes of ventricular dysfunction in children with structurally normal hearts include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cardiomyopathy</strong> – The most common cause of HF in children with a structurally normal heart is cardiomyopathy. Based on data from large registry studies, the estimated incidence of pediatric cardiomyopathy is approximately 1 case per 100,000 children per year [<a href="#rid6">6,7</a>]. Dilated cardiomyopathy accounts for 50 to 60 percent of cases, hypertrophic cardiomyopathy (HCM) accounts for 25 to 40 percent, left ventricular (LV) noncompaction accounts for 9 percent, and restrictive or other types of cardiomyopathy accounts for approximately 3 percent. (See  <a class="medical medical_review" href="/d/html/4943.html" rel="external">"Definition and classification of the cardiomyopathies"</a>.)</p><p></p><p class="bulletIndent1">Although the primary physiologic abnormality in dilated cardiomyopathy is LV systolic dysfunction, diastolic dysfunction can occur in more severe cases. In contrast, LV systolic function is usually preserved in children with HCM and restrictive cardiomyopathy; when HF occurs in these settings, it is usually due to diastolic dysfunction. HF is rare in children with HCM as most patients have preserved ventricular function. Patients with HCM who present in infancy with HF symptoms are at high risk of mortality. (See  <a class="medical medical_review" href="/d/html/4951.html" rel="external">"Hypertrophic cardiomyopathy in children: Clinical manifestations and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Myocarditis</strong> – Inflammation of the myocardium (myocarditis) is usually due to a viral infection; less commonly, it may be caused by nonviral pathogens or noninfectious causes  (<a class="graphic graphic_table graphicRef56995" href="/d/graphic/56995.html" rel="external">table 2</a>). Myocarditis often results in ventricular dysfunction and HF [<a href="#rid8">8</a>]. Acute myocarditis may be followed by either a complete recovery of LV function or a secondary dilated cardiomyopathy with chronic HF. Myocarditis is discussed in greater detail separately. (See  <a class="medical medical_review" href="/d/html/5755.html" rel="external">"Clinical manifestations and diagnosis of myocarditis in children"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Myocardial ischemia/infarction</strong> – In children, HF as a result of myocardial ischemia/infarction is uncommon:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Infants born with anomalous left coronary artery arising from the pulmonary artery (ALCAPA) usually present with symptoms and signs of myocardial ischemia/infarction and are often in HF. (See  <a class="medical medical_review" href="/d/html/1536.html" rel="external">"Congenital and pediatric coronary artery abnormalities", section on 'Variations of coronary artery origin from the pulmonary artery'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Coronary vasculitis associated with Kawasaki disease may rarely present with myocardial ischemia and LV dysfunction. (See  <a class="medical medical_review" href="/d/html/5772.html" rel="external">"Cardiovascular sequelae of Kawasaki disease: Clinical features and evaluation"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Myocardial ischemia/infarction due to premature atherosclerotic coronary artery disease is very rare in childhood but can occur in homozygous familial hypercholesterolemia. (See  <a class="medical medical_review" href="/d/html/121831.html" rel="external">"Familial hypercholesterolemia in children"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Arrhythmias</strong> – The following arrhythmias may lead to ventricular dysfunction and pediatric HF:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Complete heart block</strong> – Complete heart block may lead to HF if the junctional escape rhythm is not fast enough for the body's needs. Complete heart block is discussed in greater detail separately. (See  <a class="medical medical_review" href="/d/html/912.html" rel="external">"Congenital third-degree (complete) atrioventricular block"</a> and  <a class="medical medical_review" href="/d/html/911.html" rel="external">"Third-degree (complete) atrioventricular block"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Supraventricular and ventricular arrhythmias</strong> – Supraventricular arrhythmias (eg, supraventricular tachycardia, atrial flutter, atrial fibrillation, ectopic atrial tachycardia, or paroxysmal junctional reciprocating tachycardia), if incessant and not recognized for hours/days after onset, may result in ventricular dysfunction and HF. Similarly, junctional or ventricular tachycardia may also lead to progressive HF. It may be difficult to ascertain in a child presenting with ventricular dysfunction and a concurrent tachyarrhythmia whether the arrhythmia is the primary diagnosis (with secondary ventricular dysfunction) or is secondary to an underlying cardiomyopathy/ventricular dysfunction. Control of arrhythmia with medications or ablative methods usually leads to improved ventricular function. (See  <a class="medical medical_review" href="/d/html/5766.html" rel="external">"Irregular heart rhythm (arrhythmias) in children"</a> and  <a class="medical medical_review" href="/d/html/5783.html" rel="external">"Clinical features and diagnosis of supraventricular tachycardia (SVT) in children"</a> and  <a class="medical medical_review" href="/d/html/5758.html" rel="external">"Management and evaluation of wide QRS complex tachycardia in children", section on 'Monitoring'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Drug/toxins</strong> – Pediatric cancer patients who have been treated with chemotherapy agents, especially anthracyclines, carry a lifelong risk of developing ventricular dysfunction and HF [<a href="#rid9">9</a>]. (See  <a class="medical medical_review" href="/d/html/90854.html" rel="external">"Clinical manifestations, diagnosis, and treatment of anthracycline-induced cardiotoxicity"</a> and  <a class="medical medical_review" href="/d/html/107443.html" rel="external">"Risk and prevention of anthracycline cardiotoxicity"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Noncardiac causes</strong> – Noncardiac causes of HF due to ventricular dysfunction include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Sepsis (see  <a class="medical medical_review" href="/d/html/6395.html" rel="external">"Sepsis in children: Definitions, epidemiology, clinical manifestations, and diagnosis"</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Chronic kidney disease (see  <a class="medical medical_review" href="/d/html/128353.html" rel="external">"Chronic kidney disease in children: Complications", section on 'Risk for cardiovascular disease'</a> and  <a class="medical medical_review" href="/d/html/13606.html" rel="external">"Cardiorenal syndrome: Definition, prevalence, diagnosis, and pathophysiology"</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Respiratory disorders (eg, obstructive sleep apnea, bronchopulmonary dysplasia, cystic fibrosis, interstitial lung disease), which can cause pulmonary hypertension and right HF (see  <a class="medical medical_review" href="/d/html/17234.html" rel="external">"Pulmonary hypertension in children: Classification, evaluation, and diagnosis", section on 'Lung disease'</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>HIV infection (see  <a class="medical medical_review" href="/d/html/5963.html" rel="external">"Pediatric HIV infection: Classification, clinical manifestations, and outcome", section on 'Long-term morbidities'</a> and  <a class="medical medical_review" href="/d/html/3699.html" rel="external">"Cardiac and vascular disease in patients with HIV"</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Systemic lupus erythematous (see  <a class="medical medical_review" href="/d/html/6420.html" rel="external">"Childhood-onset systemic lupus erythematosus (SLE): Clinical manifestations and diagnosis", section on 'Cardiac'</a>)</p><p></p><p class="headingAnchor" id="H180717533"><span class="h3">Congenital heart disease</span><span class="headingEndMark"> — </span>Ventricular dysfunction may develop in children born with complex CHD who undergo surgical repair or palliation in early childhood. Although impaired ventricular function is most frequently detected by the onset of symptoms during adolescence and young adulthood, it may be detected earlier in the first decade of life on routine echocardiographic imaging in asymptomatic patients. The progression of ventricular dysfunction is variable depending on the underlying pathophysiology of the corrected cardiac defect. As long-term survival following complex CHD repair continues to improve, these patients with "burnt-out" CHD are expected to represent a growing proportion of patients with chronic HF in the general population [<a href="#rid10">10</a>]. (See  <a class="medical medical_review" href="/d/html/95232.html" rel="external">"Management of complications in patients with Fontan circulation", section on 'Heart failure'</a>.)</p><p class="headingAnchor" id="H23884808"><span class="h2">Volume overload with preserved ventricular contractility</span><span class="headingEndMark"> — </span>Volume overload may be due to cardiac or noncardiac causes:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cardiac causes</strong> – Volume overload occurs due to a moderate or large communication (shunt) between systemic and pulmonary circulations and may occur with the following cardiac lesions  (<a class="graphic graphic_table graphicRef79989" href="/d/graphic/79989.html" rel="external">table 1</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Ventricular septal defect (see  <a class="medical medical_review" href="/d/html/5787.html" rel="external">"Isolated ventricular septal defects (VSDs) in infants and children: Anatomy, clinical features, and diagnosis"</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patent ductus arteriosus (see  <a class="medical medical_review" href="/d/html/1421.html" rel="external">"Clinical manifestations and diagnosis of patent ductus arteriosus (PDA) in term infants, children, and adults"</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Atrial septal defect, rarely (see  <a class="medical medical_review" href="/d/html/5754.html" rel="external">"Isolated atrial septal defects (ASDs) in children: Classification, clinical features, and diagnosis"</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Aortopulmonary window</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Atrioventricular septal defect</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Single ventricle physiology with unobstructed pulmonary blood flow</p><p></p><p class="bulletIndent1">In the early neonatal period, infants with these defects generally do not have clinically significant left-to-right shunting, due to high pulmonary vascular resistance (PVR). During the first six to eight weeks after birth, the physiologic decline in PVR leads to a progressive increase in shunting with increase in pulmonary blood flow, pulmonary venous return, and left (systemic) ventricular preload, resulting in symptoms and signs of HF. (See  <a class="medical medical_review" href="/d/html/5773.html" rel="external">"Pathophysiology of left-to-right shunts"</a>.)</p><p></p><p class="bulletIndent1">Volume overload may also occur with valvular insufficiency from:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Aortic regurgitation, seen in some children with bicuspid aortic valves and following catheter-based intervention in patients with valvar aortic stenosis (ie, balloon aortic valvuloplasty). (See  <a class="medical medical_review" href="/d/html/5778.html" rel="external">"Aortic regurgitation in children"</a> and  <a class="medical medical_review" href="/d/html/5776.html" rel="external">"Subvalvar aortic stenosis (subaortic stenosis)"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Mitral regurgitation. (See  <a class="medical medical_review" href="/d/html/8116.html" rel="external">"Clinical manifestations and diagnosis of chronic mitral regurgitation"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Pulmonary regurgitation, seen in some children as a long-term complication following tetralogy of Fallot repair. (See  <a class="medical medical_review" href="/d/html/141526.html" rel="external">"Tetralogy of Fallot (TOF): Long-term complications and follow-up after repair", section on 'Chronic pulmonary regurgitation'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Noncardiac causes</strong> – Noncardiac causes of HF due to volume overload with preserved ventricular pump function include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Arteriovenous malformation (extracardiac shunting)</p><p class="bulletIndent2"><span class="glyph">•</span>Fluid overload (eg, oliguric renal failure)</p><p></p><p class="headingAnchor" id="H23884801"><span class="h2">Pressure overload with preserved ventricular contractility</span><span class="headingEndMark"> — </span>Pressure overload may be caused by CHD with severe ventricular outflow obstruction that impedes ejection of blood from the heart, resulting in inadequate cardiac output and/or high filling pressures. Mild outflow obstruction is asymptomatic; however, severe obstruction often presents acutely with HF (low cardiac output) in early infancy. Moderate/severe outflow obstruction may also lead to HF from chronically elevated filling pressures. Depending on severity and chronicity, pressure overload may result in either systolic or diastolic dysfunction.</p><p>The obstructive lesions associated with HF include  (<a class="graphic graphic_table graphicRef79989" href="/d/graphic/79989.html" rel="external">table 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Aortic stenosis (see  <a class="medical medical_review" href="/d/html/5775.html" rel="external">"Valvar aortic stenosis in children", section on 'Critical aortic stenosis'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Coarctation of the aorta (see  <a class="medical medical_review" href="/d/html/5760.html" rel="external">"Clinical manifestations and diagnosis of coarctation of the aorta", section on 'Manifestations according to age'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pulmonary stenosis (see  <a class="medical medical_review" href="/d/html/8120.html" rel="external">"Clinical manifestations and diagnosis of pulmonic stenosis in adults"</a>)</p><p></p><p>In addition, systemic hypertension can result in pressure overload of the heart. The ventricular function is usually preserved, but dysfunction may occur with severe hypertension. Similarly, pulmonary hypertension results in pressure overload on the right ventricle (RV) and may result in right HF. (See  <a class="medical medical_review" href="/d/html/6088.html" rel="external">"Evaluation of hypertension in children and adolescents"</a> and  <a class="medical medical_review" href="/d/html/17234.html" rel="external">"Pulmonary hypertension in children: Classification, evaluation, and diagnosis"</a>.)</p><p class="headingAnchor" id="H23884780"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>Symptoms and physical findings in children with HF reflect the patient's inability to adequately increase cardiac output (eg, exercise intolerance and easy fatigue) and/or pulmonary or systemic fluid overload (eg, shortness of breath at rest or with effort due to pulmonary interstitial edema or hepatomegaly).</p><p class="headingAnchor" id="H180717807"><span class="h2">Symptoms</span><span class="headingEndMark"> — </span>Symptoms of HF vary with the age of the patient as follows:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Infants</strong> – The most common symptoms are tachypnea and diaphoresis during feeds, easy fatigability, irritability, decreased volume of feeds, and poor weight gain. Undernutrition may result in delayed motor milestones. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Young children</strong> – In young children, symptoms may include gastrointestinal symptoms (abdominal pain, nausea, vomiting, and poor appetite), poor weight gain, easy fatigability, and recurrent or chronic cough with wheezing. These symptoms be mistaken for common childhood illnesses such as gastroenteritis, reflux, asthma, or even behavioral issues.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Older children</strong> – Older children may present with exercise intolerance, anorexia, abdominal pain, wheezing, dyspnea, edema, palpitations, chest pain, or syncope [<a href="#rid11">11</a>].</p><p></p><p>In children without underlying heart disease, the nonspecific nature of HF symptoms can present a diagnostic challenge since noncardiac causes of many of these symptoms are far more common in children than are cardiac etiologies. This was highlighted in a study of 191 children with new-onset HF presenting in the primary care or emergency department setting, of whom nearly one-half initially received a diagnosis other than HF [<a href="#rid12">12</a>]. The most common initial diagnoses included bacterial infections (pneumonia, sinusitis, otitis media), viral illnesses, gastroenteritis, and asthma. Compared with patients who were correctly diagnosed at the initial visit, patients with an initial incorrect diagnoses were older at presentation (median age 4 years versus 10 months); had a longer duration of symptoms (median seven versus three days); and more commonly presented with gastrointestinal symptoms such as abdominal pain, loss of appetite, nausea, and vomiting. A high index of suspicion is needed to distinguish HF from other far more common pediatric illnesses. (See <a class="local">'Differential diagnosis'</a> below.)</p><p>A family history of congenital heart disease (CHD) or cardiomyopathy in a sibling or parent may suggest a similar diagnosis in the child being evaluated.</p><p class="headingAnchor" id="H23884766"><span class="h2">Physical examination</span><span class="headingEndMark"> — </span>Physical findings vary depending on the cardiac output, degree of volume overload and pulmonary congestion, and/or systemic venous congestion.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tachycardia</strong> – Tachycardia is defined as the presence of a heart rate value greater than expected for age  (<a class="graphic graphic_table graphicRef78097" href="/d/graphic/78097.html" rel="external">table 3</a>). In patients with depressed myocardial contractility, tachycardia is a response to decreased stroke volume in attempt to maintain cardiac output. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Poor perfusion</strong> – Poor perfusion as a result of diminished cardiac output is manifested by cool and mottled extremities, decreased capillary refill, decreased peripheral pulses, and lowered systemic blood pressure.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Gallop rhythm</strong> – A third heart sound (S3) gallop may be present in children with diminished cardiac output or volume overload. (See  <a class="medical medical_review" href="/d/html/103723.html" rel="external">"Approach to the infant or child with a cardiac murmur", section on 'Third and fourth heart sounds'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pulmonary findings</strong> – Pulmonary congestion is manifested primarily with changes in respiratory status:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Tachypnea is the most common finding of pulmonary congestion. Normal respiratory rate varies with age  (<a class="graphic graphic_table graphicRef78097" href="/d/graphic/78097.html" rel="external">table 3</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Other signs of respiratory distress seen in patients with HF include retractions, use of accessory respiratory muscles, and grunting with nasal flaring (in infants).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Auscultatory findings, including wheezing and rales, are more commonly seen in older children as compared with infants.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Systemic congestion</strong> – Systemic congestion may be manifested by the following findings:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Hepatomegaly (the most common finding)</p><p class="bulletIndent2"><span class="glyph">•</span>Peripheral edema</p><p class="bulletIndent2"><span class="glyph">•</span>Ascites and splenomegaly (may be present in severe right HF)</p><p class="bulletIndent2"><span class="glyph">•</span>Jugular venous distension (not generally observed in infants and young children)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other findings</strong> – Other findings may suggest an underlying etiology for HF, as demonstrated by the following examples:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>High blood pressure limited to upper extremities and/or weak pulses in lower extremities are suggestive of aortic coarctation. (See  <a class="medical medical_review" href="/d/html/5760.html" rel="external">"Clinical manifestations and diagnosis of coarctation of the aorta", section on 'Blood pressure and pulses'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The presence of a systolic murmur may be seen in patients with outflow obstruction in hypertrophic cardiomyopathy or aortic stenosis, congenital heart defects with left-to-right shunting (eg, ventricular septal defects), or mitral regurgitation. (See  <a class="medical medical_review" href="/d/html/103723.html" rel="external">"Approach to the infant or child with a cardiac murmur", section on 'Heart murmurs'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Precordial examination may reveal a "thrill" in patients with shunt lesions, whereas those with a longstanding cardiomyopathy may have a "heave" with a laterally displaced point of maximal impulse. (See  <a class="medical medical_review" href="/d/html/103723.html" rel="external">"Approach to the infant or child with a cardiac murmur", section on 'Palpation of the chest'</a>.)</p><p></p><p class="headingAnchor" id="H258994897"><span class="h1">DIAGNOSTIC EVALUATION</span></p><p class="headingAnchor" id="H2346351454"><span class="h2">Goals</span><span class="headingEndMark"> — </span>The diagnosis of HF in children is based on a combination of clinical, echocardiographic, and laboratory findings. Characteristic signs and physical findings of impaired cardiac output include exercise and/or feeding intolerance, tachycardia, respiratory distress (eg, tachypnea and dyspnea), poor perfusion, and poor growth [<a href="#rid13">13,14</a>]. (See <a class="local">'Clinical manifestations'</a> above.)</p><p>Noninvasive imaging studies and laboratory tests are initially obtained to confirm the diagnosis, ascertain the severity of HF, and determine the underlying cause if unclear from the history. Evaluation should only proceed if the patient is clinically stable.</p><p class="headingAnchor" id="H2541612532"><span class="h2">Unstable patients</span><span class="headingEndMark"> — </span>In patients who have severe cardiorespiratory compromise (ie, shock or impending cardiac arrest), prompt initiation of treatment to restore adequate perfusion should be provided prior to undergoing a detailed evaluation to determine the underlying cause of HF. The initial management of shock in neonates  (<a class="graphic graphic_algorithm graphicRef128082" href="/d/graphic/128082.html" rel="external">algorithm 1</a>) and in infants and children  (<a class="graphic graphic_algorithm graphicRef129655" href="/d/graphic/129655.html" rel="external">algorithm 2</a>) is summarized in the algorithms and discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/126605.html" rel="external">"Neonatal shock: Management"</a> and  <a class="medical medical_review" href="/d/html/6397.html" rel="external">"Shock in children in resource-abundant settings: Initial management"</a>.)</p><p>Neonates presenting with unexplained shock should be started on prostaglandin infusion, which should be continued until a ductal-dependent cardiac defect is excluded using echocardiography. (See  <a class="medical medical_review" href="/d/html/5785.html" rel="external">"Diagnosis and initial management of cyanotic heart disease in the newborn", section on 'Prostaglandin E1'</a>.)</p><p class="headingAnchor" id="H529080246"><span class="h2">Initial evaluation</span><span class="headingEndMark"> — </span>The initial evaluation generally includes chest radiography, electrocardiogram (ECG), echocardiography, and laboratory tests (including brain natriuretic peptide [BNP] or N-terminal pro-BNP [NT-proBNP], troponin, complete blood count, and serum chemistries).</p><p class="headingAnchor" id="H23884687"><span class="h3">Chest radiography</span><span class="headingEndMark"> — </span>Chest radiography is helpful to assess for cardiomegaly and pulmonary congestion and to monitor the effectiveness of HF treatment. Pulmonary interstitial edema and pleural effusion are common findings in newly diagnosed HF  (<a class="graphic graphic_diagnosticimage graphicRef88511" href="/d/graphic/88511.html" rel="external">image 1</a>).</p><p>Cardiomegaly may be seen in a number of cardiac diseases, including:</p><p class="bulletIndent1"><span class="glyph">●</span>Left-to-right shunting defects – In this setting, cardiomegaly reflects the presence of a moderate to large shunt with volume overload and subsequent atrial and ventricular dilatation  (<a class="graphic graphic_diagnosticimage graphicRef93805" href="/d/graphic/93805.html" rel="external">image 2</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Dilated cardiomyopathy – Cardiomegaly reflects the dilatation of left ventricle (LV)  (<a class="graphic graphic_diagnosticimage graphicRef63664" href="/d/graphic/63664.html" rel="external">image 3</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Myocarditis – Ventricular dilation may not be severe in this setting, or ventricular size may be normal  (<a class="graphic graphic_diagnosticimage graphicRef111231" href="/d/graphic/111231.html" rel="external">image 4</a> and <a class="graphic graphic_diagnosticimage graphicRef111232" href="/d/graphic/111232.html" rel="external">image 5</a>) (see  <a class="medical medical_review" href="/d/html/5755.html" rel="external">"Clinical manifestations and diagnosis of myocarditis in children", section on 'Chest radiograph'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Arrhythmogenic right ventricular (RV) cardiomyopathy – RV dilation may sometimes be seen (see  <a class="medical medical_review" href="/d/html/110459.html" rel="external">"Arrhythmogenic right ventricular cardiomyopathy: Diagnostic evaluation and diagnosis"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Restrictive cardiomyopathy – Biatrial enlargement may be seen</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pericardial effusion</p><p></p><p>In a prospective cohort of 95 children referred to a pediatric cardiology clinic, cardiomegaly on chest radiograph had a specificity of 92.3 percent and a negative predictive value of 91.1 percent in predicting ventricular dilation on echocardiogram [<a href="#rid15">15</a>].</p><p class="headingAnchor" id="H258995466"><span class="h3">Electrocardiogram</span><span class="headingEndMark"> — </span>The ECG is an important diagnostic tool in the evaluation of a child with HF. Sinus tachycardia is the most common ECG finding and is nonspecific. It represents a physiologic compensation for reduced stroke volume.</p><p>In some cases, the ECG may point toward an underlying cause. Examples include:</p><p class="bulletIndent1"><span class="glyph">●</span>ST segment and T wave abnormalities are common in all forms of cardiomyopathy and myocarditis  (<a class="graphic graphic_waveform graphicRef76497" href="/d/graphic/76497.html" rel="external">waveform 1</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Increased QRS voltage that meets criteria for ventricular hypertrophy may be seen in hypertrophic or dilated cardiomyopathy  (<a class="graphic graphic_waveform graphicRef53365" href="/d/graphic/53365.html" rel="external">waveform 2</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Decreased QRS voltage may suggest myocardial edema or pericardial effusion and may be present in children with myocarditis  (<a class="graphic graphic_waveform graphicRef63132" href="/d/graphic/63132.html" rel="external">waveform 3</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Biatrial enlargement may be present in restrictive cardiomyopathy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A deep q wave in inferior and lateral leads (I, aVL, and V5-V6) with ST segment and T wave changes is suggestive of a myocardial infarct and is a classic finding in infants with anomalous left coronary arising from the pulmonary artery (ALCAPA)  (<a class="graphic graphic_waveform graphicRef51869" href="/d/graphic/51869.html" rel="external">waveform 4</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Varying degrees of heart block may sometimes be observed in patients with rheumatic or Lyme carditis or in patients with neonatal lupus.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Atrial, junctional, or ventricular tachycardia or frequent atrial or ventricular ectopy may suggest arrhythmia as an underlying cause of ventricular dysfunction or may represent a complication.</p><p></p><p class="headingAnchor" id="H23884680"><span class="h3">Echocardiography</span><span class="headingEndMark"> — </span>Echocardiography is the primary imaging modality to assess ventricular size and function in children with signs and symptoms of HF. It also establishes whether the child has a structurally normal heart or underlying structural congenital heart disease (CHD).</p><p>Important aspects of the echocardiogram evaluation include [<a href="#rid13">13</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Cardiac anatomy</p><p class="bulletIndent1"><span class="glyph">●</span>Arterial and venous connections</p><p class="bulletIndent1"><span class="glyph">●</span>Origin of coronary arteries</p><p class="bulletIndent1"><span class="glyph">●</span>Presence and amount of shunting</p><p class="bulletIndent1"><span class="glyph">●</span>Presence and amount of valvular stenosis and regurgitation</p><p class="bulletIndent1"><span class="glyph">●</span>Atrial and ventricular sizes (including chamber size, wall thickness, and trabeculations)</p><p class="bulletIndent1"><span class="glyph">●</span>LV and RV global and regional systolic function</p><p class="bulletIndent1"><span class="glyph">●</span>LV diastolic function</p><p class="bulletIndent1"><span class="glyph">●</span>Estimation of RV and pulmonary artery pressures</p><p class="bulletIndent1"><span class="glyph">●</span>Atrial or ventricular thrombi</p><p class="bulletIndent1"><span class="glyph">●</span>Pericardial effusion</p><p></p><p>Measurements of ventricular size, mass, and volume are compared with normalized pediatric values to account for variations by age and body size [<a href="#rid14">14</a>].</p><p>Echocardiographic findings in children with HF vary depending on the mechanism:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ventricular dysfunction</strong> – Findings that suggest ventricular dysfunction include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Impaired ventricular systolic function (eg, ejection fraction &lt;56 percent or fractional shortening &lt;29 percent [<a href="#rid16">16,17</a>])</p><p class="bulletIndent2"><span class="glyph">•</span>Enlarged or dilated ventricle(s) assessed as Z-scores of ventricular volume compared with healthy age-matched children [<a href="#rid17">17,18</a>]</p><p></p><p class="bulletIndent1">Left atrial and ventricular size may be helpful in determining chronicity. LV dilation, a spherical appearance, and eccentric hypertrophy (increased mass with normal wall thickness), often described as components of remodeling, usually suggest longstanding dilated cardiomyopathy rather than an acute process (eg, myocarditis).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Volume overload</strong> – Findings that suggest volume overload include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Atrial and/or ventricular enlargement</p><p class="bulletIndent2"><span class="glyph">•</span>Sizable septal defects with a large amount of shunting</p><p class="bulletIndent2"><span class="glyph">•</span>Severe valvar regurgitation</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pressure overload</strong> – Findings that suggest pressure overload include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Ventricular hypertrophy (eg, increased LV wall thickness)</p><p class="bulletIndent2"><span class="glyph">•</span>Severe outflow tract obstruction (eg, valvar, subvalvar, or supravalvar aortic or pulmonic stenosis)</p><p></p><p>Echocardiographic findings in specific causes of HF are discussed in detail separately:</p><p class="bulletIndent1"><span class="glyph">●</span>Dilated cardiomyopathy (see  <a class="medical medical_review" href="/d/html/3516.html" rel="external">"Causes of dilated cardiomyopathy", section on 'Definition'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hypertrophic cardiomyopathy (HCM) (see  <a class="medical medical_review" href="/d/html/4948.html" rel="external">"Hypertrophic cardiomyopathy: Clinical manifestations, diagnosis, and evaluation", section on 'Echocardiography'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Restrictive cardiomyopathy (see  <a class="medical medical_review" href="/d/html/4918.html" rel="external">"Restrictive cardiomyopathies", section on 'Echocardiography'</a>) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Arrhythmogenic RV cardiomyopathy (see  <a class="medical medical_review" href="/d/html/110459.html" rel="external">"Arrhythmogenic right ventricular cardiomyopathy: Diagnostic evaluation and diagnosis", section on 'Echocardiography'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>LV noncompaction (see  <a class="medical medical_review" href="/d/html/4924.html" rel="external">"Isolated left ventricular noncompaction in adults: Clinical manifestations and diagnosis", section on 'Echocardiography'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Myocarditis (see  <a class="medical medical_review" href="/d/html/5755.html" rel="external">"Clinical manifestations and diagnosis of myocarditis in children", section on 'Echocardiogram'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>ALCAPA (see  <a class="medical medical_review" href="/d/html/1536.html" rel="external">"Congenital and pediatric coronary artery abnormalities", section on 'Noninvasive imaging'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pulmonary hypertension (see  <a class="medical medical_review" href="/d/html/17234.html" rel="external">"Pulmonary hypertension in children: Classification, evaluation, and diagnosis", section on 'Echocardiography'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>CHD (eg, ventricular septal defect, patent ductus arteriosus, atrial septal defect) (see  <a class="medical medical_review" href="/d/html/5332.html" rel="external">"Echocardiographic evaluation of ventricular septal defects"</a> and  <a class="medical medical_review" href="/d/html/1421.html" rel="external">"Clinical manifestations and diagnosis of patent ductus arteriosus (PDA) in term infants, children, and adults", section on 'Echocardiography'</a> and  <a class="medical medical_review" href="/d/html/5754.html" rel="external">"Isolated atrial septal defects (ASDs) in children: Classification, clinical features, and diagnosis", section on 'Echocardiography'</a>)</p><p></p><p class="headingAnchor" id="H258995135"><span class="h3">Laboratory tests</span><span class="headingEndMark"> — </span>For most children who present with new onset of HF symptoms, initial laboratory tests include the following:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>BNP</strong> – BNP measurements are used to assess the severity of HF and monitor response to therapy [<a href="#rid19">19</a>].</p><p></p><p class="bulletIndent1">BNP and the inactive N-terminal fragment (NT-proBNP) levels have been extensively studied in adults and are used to assist in the diagnosis and monitoring of HF and as prognostic markers. (See  <a class="medical medical_review" href="/d/html/3486.html" rel="external">"Natriuretic peptide measurement in heart failure"</a>.)</p><p></p><p class="bulletIndent1">BNP and NT-proBNP appear to be effective markers of structural and functional heart disease in children and are useful in the integrated evaluation of children with HF [<a href="#rid14">14,19-22</a>]. The role of these markers in pediatric patients is less well established than in adults due to differences in ventricular impairment and morphology between adult and pediatric cardiac diseases and the lack of normative pediatric standards (because of variation of levels due to assay methods and age). BNP and NT-proBNP levels are higher at birth and decrease rapidly during the first days of life [<a href="#rid23">23</a>].</p><p></p><p class="bulletIndent1">BNP levels can help discriminate between cardiac disease and noncardiac causes of HF symptoms (eg, pulmonary disease) [<a href="#rid24">24-27</a>]. BNP testing has been used in a wide range of pediatric cardiac diseases, including CHD [<a href="#rid22">22,28,29</a>], myocarditis, cardiomyopathy, pulmonary hypertension, and anthracycline-induced cardiac toxicity [<a href="#rid30">30-32</a>].</p><p></p><p class="bulletIndent1">In patients with left-to-right shunting defects (eg, atrial or ventricular septal defects, patent ductus arteriosus), BNP levels correlate with the degree of shunting [<a href="#rid22">22,33</a>]; and in children with ventricular dysfunction, BNP levels correlate negatively with ejection fraction [<a href="#rid34">34-37</a>]. BNP levels also correlate with functional class of HF and with outcome [<a href="#rid22">22,26,33-39</a>]. Higher age-adjusted NT-proBNP levels have been shown to be a predictor of major adverse cardiovascular events in children with CHD [<a href="#rid40">40</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Troponin</strong> – Cardiac troponin I and troponin T are sensitive biomarkers for myocyte injury. Troponin levels are elevated in myocarditis and myocardial ischemia. Among children presenting with LV dysfunction, an elevated troponin level may suggest acute myocarditis rather than dilated cardiomyopathy [<a href="#rid41">41</a>]. (See  <a class="medical medical_review" href="/d/html/86.html" rel="external">"Troponin testing: Clinical use"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Complete blood count and iron studies</strong> – Anemia may contribute to HF in a predisposed patient (eg, one with a moderate to severe ventricular septal defect) or exacerbate the severity of HF symptoms in a patient with preexisting HF. In a single institutional study of children hospitalized for acute HF, the prevalence of anemia at the time of admission was 18 percent and nearly 40 percent of patients developed anemia at some time during the hospitalization [<a href="#rid42">42</a>]. </p><p></p><p class="bulletIndent1">In children with HF and anemia, the cause of anemia should be investigated. The evaluation should include iron studies since iron deficiency is the most common cause. Iron deficiency is particularly common in children with advanced HF and may occur even in absence of anemia [<a href="#rid43">43</a>]. (See  <a class="medical medical_review" href="/d/html/5927.html" rel="external">"Approach to the child with anemia"</a> and  <a class="medical medical_review" href="/d/html/5925.html" rel="external">"Iron deficiency in infants and children &lt;12 years: Screening, prevention, clinical manifestations, and diagnosis", section on 'Laboratory testing'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Serum chemistries</strong> – This includes electrolytes, blood urea nitrogen, creatinine, and liver function tests.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Hyponatremia may be seen in children with severe HF [<a href="#rid44">44</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Renal impairment may be a contributing factor for HF or may exacerbate preexisting failure</p><p class="bulletIndent2"><span class="glyph">•</span>Baseline electrolytes are needed prior to initiating therapy with diuretics or ACE inhibitors to avoid potential side effects of these drugs</p><p class="bulletIndent2"><span class="glyph">•</span>Liver function studies may be elevated due to hepatic congestion with right-sided HF</p><p></p><p class="headingAnchor" id="H2635969644"><span class="h2">Additional evaluation</span><span class="headingEndMark"> — </span>Additional testing in children with HF may include cardiac magnetic resonance imaging (MRI) and or cardiac catheterization if the information from echocardiography is insufficient. Ambulatory ECG testing is performed in children with symptoms suggestive of arrhythmia and in patients at risk for arrhythmia. Exercise testing may be helpful in determining the patient's functional class, particularly for children with cardiomyopathy. A three-generation pedigree is an important part of the evaluation in children with a suspected familial cause of HF (eg, cardiomyopathy). Tests to identify the underlying etiology may be warranted if the cause is unclear from the initial evaluation.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>MRI</strong> – Occasionally, the information from echocardiography is insufficient because of altered geometry, particularly in the assessment of RV and single ventricular function in children with complex CHD [<a href="#rid1">1</a>] or in patients with inflammation. In these settings, cardiac MRI can provide accurate and detailed information regarding cardiac anatomy, ventricular function, myocardial inflammation, and infiltration by fat and fibrous tissues [<a href="#rid45">45</a>]. The need for sedation, particularly in young children, is an important limitation of cardiac MRI in pediatric patients. In addition, cardiac MRI may not be available at all centers.</p><p></p><p class="bulletIndent1">Clinical settings in which cardiac MRI may have utility in pediatric HF include (see  <a class="medical medical_review" href="/d/html/5314.html" rel="external">"Clinical utility of cardiovascular magnetic resonance imaging"</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Evaluation of anatomic details in complex CHD and for providing quantitative assessment of shunts and RV function</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Distinguishing restrictive cardiomyopathy from constrictive pericarditis (see  <a class="medical medical_review" href="/d/html/4946.html" rel="external">"Differentiating constrictive pericarditis and restrictive cardiomyopathy"</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Noninvasive assessment of myocardial inflammation in patients with suspected myocarditis (see  <a class="medical medical_review" href="/d/html/5755.html" rel="external">"Clinical manifestations and diagnosis of myocarditis in children", section on 'Cardiac magnetic resonance'</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Evaluation of RV function, dilation, and fatty infiltration in patients with arrhythmogenic RV cardiomyopathy (see  <a class="medical medical_review" href="/d/html/110459.html" rel="external">"Arrhythmogenic right ventricular cardiomyopathy: Diagnostic evaluation and diagnosis"</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Assessing the extent of noncompacted myocardium in noncompaction cardiomyopathy (see  <a class="medical medical_review" href="/d/html/4924.html" rel="external">"Isolated left ventricular noncompaction in adults: Clinical manifestations and diagnosis"</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Quantitative assessment of myocardial fibrosis by measuring late gadolinium enhancement, an independent risk factor for ventricular arrhythmia and sudden cardiac death (see  <a class="medical medical_review" href="/d/html/4951.html" rel="external">"Hypertrophic cardiomyopathy in children: Clinical manifestations and diagnosis", section on 'Additional testing'</a> and  <a class="medical medical_review" href="/d/html/4948.html" rel="external">"Hypertrophic cardiomyopathy: Clinical manifestations, diagnosis, and evaluation", section on 'Cardiovascular magnetic resonance'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cardiac catheterization</strong> – Cardiac catheterization can provide useful information in the following settings:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>It may help in establishing the etiology of HF if the underlying cause remains unclear after noninvasive testing with echocardiography and/or MRI.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If the coronary anatomy is unclear or equivocal on echocardiography and there is clinical concern for a coronary anomaly (eg, ALCAPA, Kawasaki disease), coronary angiography can be helpful. (See  <a class="medical medical_review" href="/d/html/1536.html" rel="external">"Congenital and pediatric coronary artery abnormalities"</a> and  <a class="medical medical_review" href="/d/html/5772.html" rel="external">"Cardiovascular sequelae of Kawasaki disease: Clinical features and evaluation", section on 'Coronary artery abnormalities'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Cardiac catheterization with endomyocardial biopsy may be performed in the evaluation of suspected myocarditis or to differentiate restrictive cardiomyopathy from constrictive pericarditis. These issues are discussed separately. (See  <a class="medical medical_review" href="/d/html/5755.html" rel="external">"Clinical manifestations and diagnosis of myocarditis in children", section on 'Endomyocardial biopsy'</a> and  <a class="medical medical_review" href="/d/html/4946.html" rel="external">"Differentiating constrictive pericarditis and restrictive cardiomyopathy", section on 'Cardiac catheterization'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Cardiac catheterization may be performed to evaluate pulmonary vascular resistance (PVR) and vasodilator responsiveness in children with known or suspected pulmonary hypertension. (See  <a class="medical medical_review" href="/d/html/17234.html" rel="external">"Pulmonary hypertension in children: Classification, evaluation, and diagnosis", section on 'Cardiac catheterization'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Cardiac catheterization is also used to guide the need and timing of cardiac transplantation in children with HF by assessing their hemodynamic status (intracardiac pressures, pulmonary artery pressure, PVR, and cardiac output).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ambulatory ECG monitoring</strong> – Ambulatory ECG monitoring (eg, 24-hour Holter monitoring) should be performed in patients with symptoms suggestive of arrhythmia (eg, palpitations, syncope). In addition, ambulatory ECG monitoring is helpful in the assessment of children at risk for arrhythmia, including patients with cardiomyopathy, heterotaxy syndromes, congenitally corrected transposition of the great arteries, and patients who have undergone Fontan palliation or atrial switch operation [<a href="#rid13">13</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Exercise testing</strong> – For children with known or suspected cardiomyopathy who are able to perform exercise testing, this assessment can provide useful information that can be used in determining the child's functional class and can help with risk stratification (ie, risk of ventricular arrhythmia and sudden cardiac death) [<a href="#rid13">13</a>]. (See  <a class="medical medical_review" href="/d/html/6473.html" rel="external">"Exercise testing in children and adolescents: Principles and clinical application"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other studies</strong> – Additional testing may be warranted depending on the clinical findings:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with clinical evidence of myocarditis, diagnostic evaluation is performed to determine the underlying infectious etiology. (See  <a class="medical medical_review" href="/d/html/5755.html" rel="external">"Clinical manifestations and diagnosis of myocarditis in children", section on 'Etiologic evaluation'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with cardiomyopathy, studies to determine the etiology may include thyroid function tests, metabolic screening, and genetic testing. For children with newly diagnosed HF due to cardiomyopathy, referral to a clinical geneticist may be warranted since many types of cardiomyopathy may have a genetic origin, particularly HCM. (See  <a class="medical medical_review" href="/d/html/4911.html" rel="external">"Genetics of dilated cardiomyopathy"</a> and  <a class="medical medical_review" href="/d/html/4951.html" rel="external">"Hypertrophic cardiomyopathy in children: Clinical manifestations and diagnosis", section on 'Genetic testing'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with clinical findings that suggest a rheumatologic disorder, additional testing may include inflammatory markers (eg, C-reactive protein, erythrocyte sedimentation rate), antistreptolysin titers (rheumatic heart disease), and antinuclear antibody testing (collagen vascular diseases including systemic lupus erythematous). (See  <a class="medical medical_review" href="/d/html/3177.html" rel="external">"Acute rheumatic fever: Clinical manifestations and diagnosis", section on 'Diagnosis'</a> and  <a class="medical medical_review" href="/d/html/6420.html" rel="external">"Childhood-onset systemic lupus erythematosus (SLE): Clinical manifestations and diagnosis", section on 'Laboratory findings'</a>.)</p><p></p><p class="headingAnchor" id="H1207214947"><span class="h1">STAGING AND SEVERITY</span><span class="headingEndMark"> — </span>Categorization of the stage and severity of the patient's HF is important for monitoring the disease progression and guiding management decisions [<a href="#rid13">13</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Staging</strong> – The staging system of pediatric HF (stages A to D) is used to describe the development and progression of disease following exposure to a risk factor for HF  (<a class="graphic graphic_table graphicRef60553" href="/d/graphic/60553.html" rel="external">table 4</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Severity</strong> – The two main classification systems used for describing severity of pediatric HF are the New York Heart Association (NYHA) and Ross classifications  (<a class="graphic graphic_table graphicRef74339" href="/d/graphic/74339.html" rel="external">table 5</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>NYHA class</strong> – The NYHA classes (I to IV) are most commonly used to quantify the degree of functional limitation imposed by HF in adults and may be used in adolescents  (<a class="graphic graphic_table graphicRef74339" href="/d/graphic/74339.html" rel="external">table 5</a>) [<a href="#rid46">46</a>]. The NYHA classification relies on patient reporting of symptom severity and thus has limitations in infants and young children. (See  <a class="medical medical_review" href="/d/html/3477.html" rel="external">"Predictors of survival in heart failure with reduced ejection fraction", section on 'NYHA functional class'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Ross classification </strong>– The Ross HF Classification is an adaptation of the NYHA system that is used to describe HF severity in infants and children based on a history of feeding intolerance, growth problems, exercise intolerance, and physical findings  (<a class="graphic graphic_table graphicRef74339" href="/d/graphic/74339.html" rel="external">table 5</a>) [<a href="#rid47">47,48</a>]. The Ross classification has been validated in two prospective studies in infants in which the Ross class demonstrated correlation with physiologic measures of HF severity (ie, plasma levels of norepinephrine and peripheral lymphocytic beta-adrenergic receptor density) [<a href="#rid49">49,50</a>].</p><p></p><p class="headingAnchor" id="H258994852"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>Numerous noncardiac conditions can present with signs and symptoms that mimic HF. Often, the initial symptoms of HF are nonspecific (respiratory distress, abdominal pain, nausea, vomiting, poor appetite, poor weight gain), and a high index of suspicion is needed to distinguish HF from other far more common pediatric illnesses that present with these symptoms. Particular findings that should raise suspicion for HF in this setting include a gallop rhythm, tachycardia out of proportion to other symptoms, hepatomegaly, altered systemic perfusion, and/or ectopy or other abnormalities on cardiac monitoring or electrocardiogram (ECG). Additional evaluation including chest radiograph and laboratory tests (eg, brain natriuretic peptide [BNP]) can help distinguish HF from noncardiac conditions. Serial assessment of the vital signs and physical examination in response to treatment can also be informative. For example, if the patient responds to intravenous fluid resuscitation with clinical deterioration (eg, increased tachycardia, dyspnea, rales) rather than improvement, HF should be considered. Ultimately, echocardiography is necessary to confirm a cardiac etiology.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Respiratory distress</strong> – Noncardiac causes of respiratory distress in neonates include transient tachypnea of the newborn, respiratory distress syndrome, meconium aspiration, congenital diaphragmatic hernia, pneumothorax, pneumonia, and pulmonary hypoplasia. In older infants and children, common causes include pneumonia, bronchiolitis, and asthma. (See  <a class="medical medical_review" href="/d/html/4964.html" rel="external">"Overview of neonatal respiratory distress and disorders of transition"</a> and  <a class="medical medical_review" href="/d/html/16315.html" rel="external">"Causes of acute respiratory distress in children"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Poor weight gain</strong> – Other causes of poor weight gain include gastrointestinal disorders (eg, protein-milk allergy, cystic fibrosis, celiac disease), chronic infections, hyperthyroidism, and metabolic disorders. (See  <a class="medical medical_review" href="/d/html/2864.html" rel="external">"Poor weight gain in children younger than two years in resource-abundant settings: Etiology and evaluation", section on 'Causes'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Edema</strong> – Peripheral edema may be caused by renal failure, venous thrombosis, or adverse drug effects. (See  <a class="medical medical_review" href="/d/html/6096.html" rel="external">"Pathophysiology and etiology of edema in children", section on 'Etiology'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Shock</strong> – Shock may be due to overwhelming sepsis or hypovolemia. (See  <a class="medical medical_review" href="/d/html/6396.html" rel="external">"Initial evaluation of shock in children", section on 'Pathophysiology'</a>.)</p><p></p><p class="headingAnchor" id="H3822293679"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/115406.html" rel="external">"Society guideline links: Heart failure in children"</a>.)</p><p class="headingAnchor" id="H23884658"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology</strong> – Heart failure (HF) results from structural or functional cardiac disorders that impair the ability of the ventricle(s) to fill with and/or eject blood. It is estimated to affect 12,000 to 35,000 children in the United States each year. (See <a class="local">'Introduction'</a> above and <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Causes</strong> – The causes of pediatric HF can be divided into the following pathophysiologic categories  (<a class="graphic graphic_table graphicRef79989" href="/d/graphic/79989.html" rel="external">table 1</a>). (See <a class="local">'Etiology and pathophysiology'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Ventricular dysfunction</strong> may occur in both patients with a structurally normal heart (eg, cardiomyopathy, myocarditis, and complete heart block) and those with complex congenital heart disease (CHD). Although HF in patients with CHD may be present at the time of diagnosis, it is more commonly a long-term complication following surgical cardiac repair. (See <a class="local">'Ventricular dysfunction'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Volume overload with preserved ventricular contractility</strong> is most commonly due to CHD with significant left-to-right shunting of blood from the systemic to pulmonary circulation. (See <a class="local">'Volume overload with preserved ventricular contractility'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Pressure overload with preserved ventricular contractility</strong> is most commonly due to CHD with ventricular outflow obstruction. (See <a class="local">'Pressure overload with preserved ventricular contractility'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical manifestations</strong> – Symptoms and physical findings reflect a limited ability to adequately increase cardiac output (eg, exercise intolerance, easy fatigue, or gastrointestinal symptoms) and/or pulmonary or systemic fluid overload (eg, shortness of breath, tachypnea, hepatomegaly, edema). Clinical features vary with age at presentation. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnostic evaluation</strong> – The diagnosis of HF in children is based on a combination of clinical, echocardiographic, and laboratory findings. Noninvasive imaging studies and laboratory tests are initially obtained to confirm the diagnosis, ascertain the severity of HF, and determine the underlying cause if unclear from the history. (See <a class="local">'Diagnostic evaluation'</a> above.)</p><p></p><p class="bulletIndent1">The initial evaluation generally includes (see <a class="local">'Initial evaluation'</a> above): </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Chest radiography (see <a class="local">'Chest radiography'</a> above)</p><p class="bulletIndent2"><span class="glyph">•</span>Electrocardiogram (ECG) (see <a class="local">'Electrocardiogram'</a> above)</p><p class="bulletIndent2"><span class="glyph">•</span>Echocardiography (see <a class="local">'Echocardiography'</a> above)</p><p class="bulletIndent2"><span class="glyph">•</span>Laboratory tests (brain natriuretic peptide [BNP] or N-terminal pro-BNP [NT-proBNP], troponin, complete blood count, and serum chemistries) (see <a class="local">'Laboratory tests'</a> above)</p><p></p><p class="bulletIndent1">Evaluation should only proceed if the patient is clinically stable. In patients who have severe cardiorespiratory compromise (ie, shock or impending cardiac arrest), prompt initiation of treatment to restore adequate perfusion should be provided prior to undergoing a detailed evaluation to determine the underlying cause of HF  (<a class="graphic graphic_algorithm graphicRef129655" href="/d/graphic/129655.html" rel="external">algorithm 2</a> and <a class="graphic graphic_algorithm graphicRef128082" href="/d/graphic/128082.html" rel="external">algorithm 1</a>). (See  <a class="medical medical_review" href="/d/html/6397.html" rel="external">"Shock in children in resource-abundant settings: Initial management"</a> and  <a class="medical medical_review" href="/d/html/126605.html" rel="external">"Neonatal shock: Management"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Staging and severity</strong> – Categorization of the stage and severity of the patient's HF is important for monitoring the disease progression and guiding management decisions. The staging system of pediatric HF (stages A to D) is used to describe the development and progression of disease following exposure to a risk factor for HF  (<a class="graphic graphic_table graphicRef60553" href="/d/graphic/60553.html" rel="external">table 4</a>). The New York Heart Association (NYHA) class is most commonly used to quantify the degree of functional limitation imposed by HF in adults and may be used in adolescents  (<a class="graphic graphic_table graphicRef74339" href="/d/graphic/74339.html" rel="external">table 5</a>). The Ross HF classification is an adaptation of the NYHA system that is used to describe HF severity in infants and children  (<a class="graphic graphic_table graphicRef74339" href="/d/graphic/74339.html" rel="external">table 5</a>). (See <a class="local">'Staging and severity'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis</strong> – Numerous noncardiac conditions can present with signs and symptoms that mimic HF. The clinical history and physical examination can distinguish HF from many of these disorders, though echocardiography and other testing (eg, ECG, chest radiograph, BNP) may ultimately be necessary to confirm the diagnosis. (See <a class="local">'Differential diagnosis'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Hsu DT, Pearson GD. Heart failure in children: part I: history, etiology, and pathophysiology. Circ Heart Fail 2009; 2:63.</a></li><li><a class="nounderline abstract_t">Rossano JW, Kim JJ, Decker JA, et al. Prevalence, morbidity, and mortality of heart failure-related hospitalizations in children in the United States: a population-based study. J Card Fail 2012; 18:459.</a></li><li><a class="nounderline abstract_t">Mejia EJ, O'Connor MJ, Lin KY, et al. Characteristics and Outcomes of Pediatric Heart Failure-Related Emergency Department Visits in the United States: A Population-Based Study. J Pediatr 2018; 193:114.</a></li><li><a class="nounderline abstract_t">Amdani S, Marino BS, Rossano J, et al. Burden of Pediatric Heart Failure in the United States. J Am Coll Cardiol 2022; 79:1917.</a></li><li><a class="nounderline abstract_t">Lasa JJ, Gaies M, Bush L, et al. Epidemiology and Outcomes of Acute Decompensated Heart Failure in Children. Circ Heart Fail 2020; 13:e006101.</a></li><li><a class="nounderline abstract_t">Lipshultz SE, Sleeper LA, Towbin JA, et al. The incidence of pediatric cardiomyopathy in two regions of the United States. N Engl J Med 2003; 348:1647.</a></li><li><a class="nounderline abstract_t">Nugent AW, Daubeney PE, Chondros P, et al. The epidemiology of childhood cardiomyopathy in Australia. N Engl J Med 2003; 348:1639.</a></li><li><a class="nounderline abstract_t">Canter CE, Simpson KE. Diagnosis and treatment of myocarditis in children in the current era. Circulation 2014; 129:115.</a></li><li><a class="nounderline abstract_t">Raj S, Franco VI, Lipshultz SE. Anthracycline-induced cardiotoxicity: a review of pathophysiology, diagnosis, and treatment. Curr Treat Options Cardiovasc Med 2014; 16:315.</a></li><li><a class="nounderline abstract_t">Book WM. Heart failure in the adult patient with congenital heart disease. J Card Fail 2005; 11:306.</a></li><li><a class="nounderline abstract_t">Hollander SA, Addonizio LJ, Chin C, et al. Abdominal complaints as a common first presentation of heart failure in adolescents with dilated cardiomyopathy. Am J Emerg Med 2013; 31:684.</a></li><li><a class="nounderline abstract_t">Puri K, Singh H, Denfield SW, et al. Missed Diagnosis of New-Onset Systolic Heart Failure at First Presentation in Children with No Known Heart Disease. J Pediatr 2019; 208:258.</a></li><li><a class="nounderline abstract_t">Kirk R, Dipchand AI, Rosenthal DN, et al. The International Society for Heart and Lung Transplantation Guidelines for the management of pediatric heart failure: Executive summary. [Corrected]. J Heart Lung Transplant 2014; 33:888.</a></li><li><a class="nounderline abstract_t">Hsu DT, Pearson GD. Heart failure in children: part II: diagnosis, treatment, and future directions. Circ Heart Fail 2009; 2:490.</a></li><li><a class="nounderline abstract_t">Satou GM, Lacro RV, Chung T, et al. Heart size on chest x-ray as a predictor of cardiac enlargement by echocardiography in children. Pediatr Cardiol 2001; 22:218.</a></li><li><a class="nounderline abstract_t">Lang RM, Bierig M, Devereux RB, et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005; 18:1440.</a></li><li><a class="nounderline abstract_t">Sluysmans T, Colan SD. Theoretical and empirical derivation of cardiovascular allometric relationships in children. J Appl Physiol (1985) 2005; 99:445.</a></li><li class="breakAll">Boston Children's Hospital Z-score calculator. The Boston Children’s Hospital z-score system is based on data gathered over 12 years on normal children. Available at: http://zscore.chboston.org/.</li><li><a class="nounderline abstract_t">Favilli S, Frenos S, Lasagni D, et al. The use of B-type natriuretic peptide in paediatric patients: a review of literature. J Cardiovasc Med (Hagerstown) 2009; 10:298.</a></li><li><a class="nounderline abstract_t">Neves AL, Henriques-Coelho T, Leite-Moreira A, Areias JC. The Utility of Brain Natriuretic Peptide in Pediatric Cardiology: A Review. Pediatr Crit Care Med 2016; 17:e529.</a></li><li><a class="nounderline abstract_t">Cantinotti M, Law Y, Vittorini S, et al. The potential and limitations of plasma BNP measurement in the diagnosis, prognosis, and management of children with heart failure due to congenital cardiac disease: an update. Heart Fail Rev 2014; 19:727.</a></li><li><a class="nounderline abstract_t">Eindhoven JA, van den Bosch AE, Boersma E, Roos-Hesselink JW. The usefulness of brain natriuretic peptide in simple congenital heart disease - a systematic review. Cardiol Young 2013; 23:315.</a></li><li><a class="nounderline abstract_t">Mir TS, Marohn S, Läer S, et al. Plasma concentrations of N-terminal pro-brain natriuretic peptide in control children from the neonatal to adolescent period and in children with congestive heart failure. Pediatrics 2002; 110:e76.</a></li><li><a class="nounderline abstract_t">Ko HK, Lee JH, Choi BM, et al. Utility of the rapid B-type natriuretic peptide assay for detection of cardiovascular problems in newborn infants with respiratory difficulties. Neonatology 2008; 94:16.</a></li><li><a class="nounderline abstract_t">Koulouri S, Acherman RJ, Wong PC, et al. Utility of B-type natriuretic peptide in differentiating congestive heart failure from lung disease in pediatric patients with respiratory distress. Pediatr Cardiol 2004; 25:341.</a></li><li><a class="nounderline abstract_t">Law YM, Hoyer AW, Reller MD, Silberbach M. Accuracy of plasma B-type natriuretic peptide to diagnose significant cardiovascular disease in children: the Better Not Pout Children! Study. J Am Coll Cardiol 2009; 54:1467.</a></li><li><a class="nounderline abstract_t">Maher KO, Reed H, Cuadrado A, et al. B-type natriuretic peptide in the emergency diagnosis of critical heart disease in children. Pediatrics 2008; 121:e1484.</a></li><li><a class="nounderline abstract_t">Law YM, Ettedgui J, Beerman L, et al. Comparison of plasma B-type natriuretic peptide levels in single ventricle patients with systemic ventricle heart failure versus isolated cavopulmonary failure. Am J Cardiol 2006; 98:520.</a></li><li><a class="nounderline abstract_t">Lowenthal A, Camacho BV, Lowenthal S, et al. Usefulness of B-type natriuretic peptide and N-terminal pro-B-type natriuretic peptide as biomarkers for heart failure in young children with single ventricle congenital heart disease. Am J Cardiol 2012; 109:866.</a></li><li><a class="nounderline abstract_t">Hayakawa H, Komada Y, Hirayama M, et al. Plasma levels of natriuretic peptides in relation to doxorubicin-induced cardiotoxicity and cardiac function in children with cancer. Med Pediatr Oncol 2001; 37:4.</a></li><li><a class="nounderline abstract_t">Pinarli FG, Oğuz A, Tunaoğlu FS, et al. Late cardiac evaluation of children with solid tumors after anthracycline chemotherapy. Pediatr Blood Cancer 2005; 44:370.</a></li><li><a class="nounderline abstract_t">Aggarwal S, Pettersen MD, Bhambhani K, et al. B-type natriuretic peptide as a marker for cardiac dysfunction in anthracycline-treated children. Pediatr Blood Cancer 2007; 49:812.</a></li><li><a class="nounderline abstract_t">Holmström H, Hall C, Thaulow E. Plasma levels of natriuretic peptides and hemodynamic assessment of patent ductus arteriosus in preterm infants. Acta Paediatr 2001; 90:184.</a></li><li><a class="nounderline abstract_t">Sugimoto M, Manabe H, Nakau K, et al. The role of N-terminal pro-B-type natriuretic peptide in the diagnosis of congestive heart failure in children. - Correlation with the heart failure score and comparison with B-type natriuretic peptide -. Circ J 2010; 74:998.</a></li><li><a class="nounderline abstract_t">Mangat J, Carter C, Riley G, et al. The clinical utility of brain natriuretic peptide in paediatric left ventricular failure. Eur J Heart Fail 2009; 11:48.</a></li><li><a class="nounderline abstract_t">Price JF, Thomas AK, Grenier M, et al. B-type natriuretic peptide predicts adverse cardiovascular events in pediatric outpatients with chronic left ventricular systolic dysfunction. Circulation 2006; 114:1063.</a></li><li><a class="nounderline abstract_t">Nasser N, Perles Z, Rein AJJT, Nir A. NT-proBNP as a marker for persistent cardiac disease in children with history of dilated cardiomyopathy and myocarditis. Pediatr Cardiol 2006; 27:87.</a></li><li><a class="nounderline abstract_t">Auerbach SR, Richmond ME, Lamour JM, et al. BNP levels predict outcome in pediatric heart failure patients: post hoc analysis of the Pediatric Carvedilol Trial. Circ Heart Fail 2010; 3:606.</a></li><li><a class="nounderline abstract_t">Sachdeva S, Song X, Dham N, et al. Analysis of clinical parameters and cardiac magnetic resonance imaging as predictors of outcome in pediatric myocarditis. Am J Cardiol 2015; 115:499.</a></li><li><a class="nounderline abstract_t">Palm J, Holdenrieder S, Hoffmann G, et al. Predicting Major Adverse Cardiovascular Events in Children With Age-Adjusted NT-proBNP. J Am Coll Cardiol 2021; 78:1890.</a></li><li><a class="nounderline abstract_t">Soongswang J, Durongpisitkul K, Nana A, et al. Cardiac troponin T: a marker in the diagnosis of acute myocarditis in children. Pediatr Cardiol 2005; 26:45.</a></li><li><a class="nounderline abstract_t">Goldberg JF, Shah MD, Kantor PF, et al. Prevalence and Severity of Anemia in Children Hospitalized with Acute Heart Failure. Congenit Heart Dis 2016; 11:622.</a></li><li><a class="nounderline abstract_t">Puri K, Price JF, Spinner JA, et al. Iron Deficiency Is Associated with Adverse Outcomes in Pediatric Heart Failure. J Pediatr 2020; 216:58.</a></li><li><a class="nounderline abstract_t">Price JF, Kantor PF, Shaddy RE, et al. Incidence, Severity, and Association With Adverse Outcome of Hyponatremia in Children Hospitalized With Heart Failure. Am J Cardiol 2016; 118:1006.</a></li><li><a class="nounderline abstract_t">Attili AK, Parish V, Valverde I, et al. Cardiovascular MRI in childhood. Arch Dis Child 2011; 96:1147.</a></li><li class="breakAll">Criteria Committee of the New York Heart Association. Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels, 9th ed, Little, Brown &amp; Co., Boston 1994.</li><li><a class="nounderline abstract_t">Ross RD, Bollinger RO, Pinsky WW. Grading the severity of congestive heart failure in infants. Pediatr Cardiol 1992; 13:72.</a></li><li><a class="nounderline abstract_t">Ross RD. The Ross classification for heart failure in children after 25 years: a review and an age-stratified revision. Pediatr Cardiol 2012; 33:1295.</a></li><li><a class="nounderline abstract_t">Ross RD, Daniels SR, Schwartz DC, et al. Plasma norepinephrine levels in infants and children with congestive heart failure. Am J Cardiol 1987; 59:911.</a></li><li><a class="nounderline abstract_t">Wu JR, Chang HR, Huang TY, et al. Reduction in lymphocyte beta-adrenergic receptor density in infants and children with heart failure secondary to congenital heart disease. Am J Cardiol 1996; 77:170.</a></li></ol></div><div id="topicVersionRevision">Topic 14373 Version 35.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19808316" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Heart failure in children: part I: history, etiology, and pathophysiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22633303" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Prevalence, morbidity, and mortality of heart failure-related hospitalizations in children in the United States: a population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29221691" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Characteristics and Outcomes of Pediatric Heart Failure-Related Emergency Department Visits in the United States: A Population-Based Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35550689" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Burden of Pediatric Heart Failure in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32301336" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Epidemiology and Outcomes of Acute Decompensated Heart Failure in Children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12711739" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : The incidence of pediatric cardiomyopathy in two regions of the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12711738" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : The epidemiology of childhood cardiomyopathy in Australia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24396015" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Diagnosis and treatment of myocarditis in children in the current era.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24748018" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Anthracycline-induced cardiotoxicity: a review of pathophysiology, diagnosis, and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15880341" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Heart failure in the adult patient with congenital heart disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23380118" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Abdominal complaints as a common first presentation of heart failure in adolescents with dilated cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30679055" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Missed Diagnosis of New-Onset Systolic Heart Failure at First Presentation in Children with No Known Heart Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25110323" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : The International Society for Heart and Lung Transplantation Guidelines for the management of pediatric heart failure: Executive summary. [Corrected].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19808380" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Heart failure in children: part II: diagnosis, treatment, and future directions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11343146" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Heart size on chest x-ray as a predictor of cardiac enlargement by echocardiography in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16376782" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15557009" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Theoretical and empirical derivation of cardiovascular allometric relationships in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15557009" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Theoretical and empirical derivation of cardiovascular allometric relationships in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19430339" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : The use of B-type natriuretic peptide in paediatric patients: a review of literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27749513" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : The Utility of Brain Natriuretic Peptide in Pediatric Cardiology: A Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24473828" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : The potential and limitations of plasma BNP measurement in the diagnosis, prognosis, and management of children with heart failure due to congenital cardiac disease: an update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22995441" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : The usefulness of brain natriuretic peptide in simple congenital heart disease - a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12456943" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Plasma concentrations of N-terminal pro-brain natriuretic peptide in control children from the neonatal to adolescent period and in children with congestive heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18097153" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Utility of the rapid B-type natriuretic peptide assay for detection of cardiovascular problems in newborn infants with respiratory difficulties.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15054559" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Utility of B-type natriuretic peptide in differentiating congestive heart failure from lung disease in pediatric patients with respiratory distress.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19796740" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Accuracy of plasma B-type natriuretic peptide to diagnose significant cardiovascular disease in children: the Better Not Pout Children! Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18519452" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : B-type natriuretic peptide in the emergency diagnosis of critical heart disease in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16893709" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Comparison of plasma B-type natriuretic peptide levels in single ventricle patients with systemic ventricle heart failure versus isolated cavopulmonary failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22196786" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Usefulness of B-type natriuretic peptide and N-terminal pro-B-type natriuretic peptide as biomarkers for heart failure in young children with single ventricle congenital heart disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11466716" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Plasma levels of natriuretic peptides in relation to doxorubicin-induced cardiotoxicity and cardiac function in children with cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15602715" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Late cardiac evaluation of children with solid tumors after anthracycline chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17171687" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : B-type natriuretic peptide as a marker for cardiac dysfunction in anthracycline-treated children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11236049" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Plasma levels of natriuretic peptides and hemodynamic assessment of patent ductus arteriosus in preterm infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20378998" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : The role of N-terminal pro-B-type natriuretic peptide in the diagnosis of congestive heart failure in children. - Correlation with the heart failure score and comparison with B-type natriuretic peptide -.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19147456" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : The clinical utility of brain natriuretic peptide in paediatric left ventricular failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16940194" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : B-type natriuretic peptide predicts adverse cardiovascular events in pediatric outpatients with chronic left ventricular systolic dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16132296" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : NT-proBNP as a marker for persistent cardiac disease in children with history of dilated cardiomyopathy and myocarditis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20573993" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : BNP levels predict outcome in pediatric heart failure patients: post hoc analysis of the Pediatric Carvedilol Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25554534" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Analysis of clinical parameters and cardiac magnetic resonance imaging as predictors of outcome in pediatric myocarditis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34736565" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Predicting Major Adverse Cardiovascular Events in Children With Age-Adjusted NT-proBNP.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15793653" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Cardiac troponin T: a marker in the diagnosis of acute myocarditis in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27060888" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Prevalence and Severity of Anemia in Children Hospitalized with Acute Heart Failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31610927" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Iron Deficiency Is Associated with Adverse Outcomes in Pediatric Heart Failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27530824" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Incidence, Severity, and Association With Adverse Outcome of Hyponatremia in Children Hospitalized With Heart Failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20880939" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Cardiovascular MRI in childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20880939" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Cardiovascular MRI in childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1614922" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Grading the severity of congestive heart failure in infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22476605" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : The Ross classification for heart failure in children after 25 years: a review and an age-stratified revision.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3825955" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Plasma norepinephrine levels in infants and children with congestive heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8546086" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Reduction in lymphocyte beta-adrenergic receptor density in infants and children with heart failure secondary to congenital heart disease.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
